Vitamin K2 Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Vitamin K2 dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Vitamin K2.
Dosing Protocols
Beginner Vitamin K2 Protocol (6-8 weeks):
- Week 1-2: Start MK-7 100 mcg daily, taken with breakfast (ideally a meal containing some fat: eggs, butter, full-fat yogurt, avocado, or alongside other fat-soluble supplements).
- Week 3-4: If tolerated (which is nearly universal), continue at 100 mcg daily. Beginners who are also taking high-dose vitamin D (4,000 IU+) may choose to step up to 150-200 mcg.
- Week 5-8: Stabilize at 100-200 mcg MK-7 daily indefinitely. The biological effects on osteocalcin and MGP carboxylation normalize over 2-4 weeks at this dose; bone-health and arterial-health benefits accumulate over months to years.
Typical beginner stack:
- Vitamin D3 2,000-4,000 IU with breakfast
- Vitamin K2 (MK-7) 100-200 mcg with breakfast (many products combine D3+K2 in a single capsule)
- Magnesium glycinate 200-400 mg elemental (evening)
- Omega-3 EPA+DHA 1-2 g with any meal
- Balanced diet with protein, leafy greens (K1 source), fermented foods, and some natto or hard cheese if tolerated (K2 dietary sources)
Cost at beginner level: approximately $8-15 per month for MK-7 alone; $20-40 for the full foundational stack listed above.
Expected outcomes at beginner level: normalization of extrahepatic vitamin K status markers (ucOC, dp-ucMGP) within 4-6 weeks if measured; no immediate subjective change; cumulative bone and vascular protection over years.
Intermediate Vitamin K2 Protocol (targeted goals):
For postmenopausal women focused on bone health:
- MK-7 180 mcg daily (Knapen trial dose, PMID 23525894)
- Plus vitamin D3 2,000-4,000 IU daily (maintain 25(OH)D 40-60 ng/mL)
- Plus magnesium glycinate 400 mg elemental daily
- Plus calcium from food or 500 mg supplement if diet inadequate
- Plus weight-bearing and resistance exercise (critical; supplement cannot substitute)
- Plus adequate protein (1.0-1.2 g/kg/day)
- Expect bone-marker improvements (ucOC, CTx, P1NP) within 3 months; DEXA BMD changes visible by 1-3 years
- Consider baseline DEXA and follow-up at 1-2 year intervals
For individuals with high cardiovascular risk or family history of arterial calcification:
- MK-7 180-200 mcg daily
- Plus vitamin D3 2,000-4,000 IU daily (optimize 25(OH)D)
- Plus omega-3 EPA/DHA 2-4 g daily (see /compound/omega-3-fatty-acids)
- Plus magnesium glycinate or taurate 300-400 mg elemental daily
- Plus whatever primary prevention is indicated (statin per guidelines, BP control, metabolic health optimization)
- Consider baseline and follow-up coronary artery calcium (CAC) scan (though current evidence doesn't confirm K2 reverses CAC, it may slow progression)
- dp-ucMGP can be measured at specialty labs to confirm K2 adequacy
For CKD patients concerned about calciphylaxis (coordinated with nephrologist):
- MK-7 180-360 mcg daily (higher dose reflects impaired baseline status and ongoing vascular calcification risk)
- Plus nephrology team coordination on calcium/phosphate/PTH management
- Plus careful anticoagulation choice: DOACs preferred over warfarin when feasible
- Plus magnesium as tolerated by renal function
- Clinical trials ongoing; not yet standard-of-care but reasonable under clinician direction
For vitamin D optimization at high doses (if taking D3 5,000+ IU daily):
- MK-7 200 mcg daily
- Consider also MK-4 5-15 mg daily for short-term peripheral K activity
- Rationale: higher D doses mobilize more calcium, increasing demand for MGP and osteocalcin activation
- Verify 25(OH)D in optimal range (40-80 ng/mL); avoid targeting >100 ng/mL
For athletes focused on bone stress injury prevention:
- MK-7 180 mcg daily
- Plus adequate energy intake (avoid RED-S/relative energy deficiency)
- Plus calcium 1,000-1,200 mg/day from food + supplement if needed
- Plus vitamin D3 2,000-4,000 IU daily
- Plus collagen peptides 10-15 g with vitamin C before weight-bearing activity (Shaw et al. collagen synthesis data)
- Plus resistance training 2-3x weekly
Typical intermediate cost: $15-25 per month for K2; $40-80 for the targeted stacks above.
Intermediate users should consider baseline lab work: 25(OH)D, serum calcium, serum phosphate, PTH, magnesium (serum and ideally RBC), ferritin, CBC, basic metabolic panel. Specialty biomarkers (ucOC, dp-ucMGP) are informative but not widely available.
Advanced Vitamin K2 Protocol (clinical-condition focused or high-dose investigational):
For established osteoporosis (adjunct to prescription therapy):
- MK-4 45 mg/day (Japanese osteoporosis guideline dose; Glakay, Shiraki regimen) split TID (morning, noon, evening) due to short half-life
- OR alternative: MK-7 360 mcg daily (investigational higher dose)
- Plus bisphosphonate, denosumab, or romosozumab as prescribed
- Plus vitamin D3 2,000-5,000 IU to target 25(OH)D 40-60 ng/mL
- Plus calcium 1,000-1,200 mg daily (food + supplement if needed)
- Plus magnesium 400 mg elemental daily
- Plus weight-bearing and resistance exercise as tolerated
- Plus protein 1.2-1.5 g/kg daily (spread across meals)
- DEXA every 1-2 years; bone turnover markers (CTx, P1NP) to monitor response
- This high-dose MK-4 should be coordinated with endocrinologist; does not meaningfully affect INR in non-warfarin patients but changes warfarin dose requirements if anticoagulated
For established vascular calcification / CAC progression:
- MK-7 360-720 mcg daily (investigational range; higher doses based on dp-ucMGP normalization targets)
- Plus vitamin D3 optimized to 25(OH)D 40-60 ng/mL
- Plus magnesium 400-600 mg elemental daily
- Plus omega-3 EPA/DHA 3-4 g daily
- Plus statin and/or other atherosclerosis therapy as indicated
- Plus blood pressure and glycemic optimization
- dp-ucMGP at baseline and 6 months to titrate dose; target upper-quartile normal
- Repeat CAC scan at 1-2 years (though CAC typically progresses regardless; goal is slower progression)
For HCC recurrence prevention after curative therapy (coordinated with hepatologist):
- MK-4 45 mg daily split TID (Mizuta protocol)
- This is investigational; evidence base is conflicting. Not standard-of-care in Western practice. Discuss with hepatologist.
For hemodialysis patients with calciphylaxis risk:
- MK-7 360-720 mcg daily
- Plus transition from warfarin to DOAC if anticoagulation is indicated (coordinate with nephrology/cardiology)
- Plus calcium/phosphate management per nephrology
- Plus magnesium per nephrology (higher serum Mg associated with better outcomes in some dialysis cohorts)
- Investigational protocol; trials ongoing
For familial or genetic accelerated calcification (Keutel syndrome, pseudoxanthoma elasticum, others):
- Clinical genetics and cardiology consultation essential
- MK-7 higher-dose protocols (360-1,000 mcg) under investigation
- Individualized based on genetic diagnosis
Biomarker-guided titration (research-grade approach):
- Baseline: 25(OH)D, 1,25(OH)2D, serum calcium, phosphate, PTH, magnesium, ucOC, cOC, dp-ucMGP, CTx, P1NP, DEXA, CAC
- Start K2 (MK-7 180 mcg or MK-4 15 mg daily)
- Recheck ucOC and dp-ucMGP at 6-8 weeks; goal to drive ucOC/cOC ratio into lower-third and dp-ucMGP into upper-third normal range
- Titrate dose based on response; some individuals require 360+ mcg MK-7 to normalize markers
- Recheck 6-monthly until stable
Advanced form rotation: Some protocols combine MK-4 (short half-life, high tissue concentration when dosed) with MK-7 (long half-life, sustained baseline):
- MK-4 5-15 mg with breakfast
- MK-7 100-200 mcg with breakfast
- Rationale: pulsed peak MK-4 activity plus steady MK-7 floor
- Evidence for this combination being superior to MK-7 alone is limited; based on mechanistic reasoning
Monitoring at advanced level:
- Every 3-6 months: CMP, CBC, 25(OH)D, magnesium
- Every 6-12 months: dp-ucMGP, ucOC (if available)
- Every 1-2 years: DEXA (if bone-focused), CAC (if vascular-focused)
- Any new bleeding, bruising, or changes to anticoagulation: immediate clinician contact
Cost at advanced level: MK-4 45 mg/day from pharmaceutical-grade products can exceed $80-150/month; MK-7 at 360 mcg is more modest ($25-40/month). Total advanced stack with K2, D3, Mg, omega-3, calcium, testing: $100-200/month.
Advanced protocols should be undertaken with clinician oversight given the narrower margin between "nutritional" and "pharmacologic" dosing at this level, and the importance of integrating with prescription therapies for the underlying condition.
Commonly Stacked With
Vitamin K2 integrates seamlessly with most foundational stacks and specifically enhances several. The key relationships are detailed below.
Vitamin D (the flagship pairing): D3 + K2 is arguably the most well-known biohacker stack pairing, and for good reason. Vitamin D increases calcium absorption from the gut and upregulates osteocalcin production by osteoblasts. Without adequate K2, the newly-produced osteocalcin remains undercarboxylated and fails to direct calcium effectively to bone, while MGP (matrix Gla protein) in vascular smooth muscle remains undercarboxylated and fails to prevent arterial calcium deposition. The consequence is that high-dose D3 without K2 may theoretically worsen arterial calcification in susceptible individuals while providing sub-optimal bone benefit—Masterjohn's 2007 review first popularized this concern, and though the clinical magnitude at typical D doses (2,000-4,000 IU) is debated, the mechanistic logic is sound and the cost of adding K2 is trivial. Practical recommendation: anyone taking vitamin D 1,000 IU or more daily should also take MK-7 100-200 mcg daily (or MK-4 5-15 mg daily, though MK-7 is simpler given its longer half-life). Some combination products deliver both in one capsule; separate dosing works equally well. See /compound/vitamin-d for the complete vitamin D picture.
Magnesium: Magnesium is required for multiple enzymes in vitamin D metabolism and activation, including CYP27B1 which converts 25(OH)D to the active hormonal form. Magnesium deficiency blunts vitamin D's effects regardless of K2 status. Practical stack: D3 2,000-4,000 IU + K2 MK-7 100-200 mcg + magnesium glycinate 300-400 mg elemental, all taken daily (D and K2 with a fat-containing meal for absorption; magnesium preferentially at bedtime). See /compound/magnesium.
Calcium: The classical calcium + D supplementation for bone health is substantially improved by adding K2, which directs absorbed calcium to bone rather than soft tissue. Whether dietary calcium alone (dairy, leafy greens, sardines) is usually sufficient without supplementation is a separate question—most adults can meet calcium needs from food, and supplemental calcium without K2 is associated in some meta-analyses with modestly increased cardiovascular risk (Bolland et al., PMID 20671013). If supplementing calcium, always pair with K2. Dose: calcium 500-1,000 mg daily (from food ideally) + D3 + K2.
Omega-3 fatty acids (EPA/DHA): K2 is fat-soluble and absorbs better with dietary fat; taking K2 with a fish oil capsule or DHA-rich meal improves bioavailability. No specific biochemical synergy beyond absorption, but the pairing is convenient. See /compound/omega-3-fatty-acids.
Boron: Small but consistent observational evidence suggests boron (3-10 mg daily) supports bone metabolism, partly via effects on vitamin D and estrogen metabolism. Boron is a reasonable addition to a bone-focused stack alongside D3, K2, Mg, and calcium.
Vitamin C: Vitamin C is required for collagen synthesis (proline and lysine hydroxylation), complementing K2's role in bone mineralization. For bone health, collagen quality (vitamin C and protein adequacy) and mineral direction (K2, Mg, Ca) are both necessary.
Glycine: As the most abundant amino acid in collagen (comprising roughly 33% of collagen residues), glycine supplementation (5-10 g daily) supports collagen synthesis and thereby bone and connective tissue structure. Pair with K2 for a more complete bone-health protocol. See /compound/glycine.
Protein: Adequate dietary protein (0.8-1.2 g/kg body weight daily, higher in older adults) supports bone and lean mass maintenance. K2's effects are not protein-dependent, but the broader bone-health picture requires adequate protein in addition to micronutrient optimization.
Exercise (especially weight-bearing and resistance): Mechanical loading of bone stimulates osteoblast activity and bone mineralization. K2's role in activating osteocalcin maximizes the bone-building response to exercise. No supplement substitutes for exercise in bone-health contexts; exercise + K2 + D3 + Mg + protein is the foundational approach.
Testosterone / HRT: Sex hormones critically influence bone mineral density. Supplementation cannot replace adequate sex hormone status in hypogonadal individuals. K2 is a complementary addition to appropriate HRT where indicated.
K2 with K1: Not antagonistic, but not strictly necessary to supplement both. Dietary K1 from leafy greens (spinach, kale, collards) is generally abundant in reasonable diets, and endogenous conversion provides some K2 from dietary K1 in peripheral tissues. Supplementation focus is on K2 specifically.
Caffeine and alcohol: Heavy chronic use of either is associated with bone mineral density loss. These should be moderated as part of a bone-health strategy; K2 does not meaningfully counteract excess of either.
Stacks to avoid or manage carefully:
- Warfarin or other vitamin K antagonists: Do NOT add K2 without coordination with your anticoagulation clinic. If added, maintain consistent dose to allow warfarin dose titration.
- Very-high-dose vitamin A (retinol >10,000 IU chronically): Can antagonize vitamin D and compete in some overlapping metabolic pathways. Avoid high-dose retinol unless specifically indicated.
- Mineral oil or long-term orlistat: Can reduce fat-soluble vitamin absorption including K2. Separate dosing by several hours.
Timing considerations:
- K2 (like D) is fat-soluble; take with a meal containing some fat for best absorption.
- Once-daily dosing of MK-7 is sufficient due to its 72-hour half-life.
- MK-4's short half-life (1-3 hours) makes once-daily dosing inefficient; if using MK-4 at lower (<15 mg) doses, split to 2-3 times daily, or choose MK-7 instead.
- No specific timing relationship to other supplements beyond the shared-fat-meal suggestion.
Complete foundational stack example (sunrise/daily):
- Breakfast (with some fat): vitamin D3 2,000-4,000 IU + K2 (MK-7) 100-200 mcg + omega-3 2 g
- Anytime: magnesium glycinate 200-400 mg elemental (often at bedtime)
- Anytime: zinc picolinate 15 mg (with a meal)
- Anytime: creatine 5 g (in water, any time)
- Anytime: glycine 3-5 g (often at bedtime)
- Anytime: taurine 2-3 g This is the "complete the basics first" approach that BodyHackGuide generally recommends before investing in more exotic compounds.
In summary, K2 fits cleanly into any foundational stack and specifically unlocks optimal tissue targeting for the D/Mg/Ca axis. The single critical interaction to manage is with warfarin.
Side Effects & Safety
Contraindications
**Absolute contraindications:** - **Concurrent warfarin, acenocoumarol, phenprocoumon, or other vitamin K antagonist therapy WITHOUT anticoagulation clinic coordination.** Starting, stopping, or changing K2 dose can destabilize INR and risk thrombosis or bleeding. This is the single most important contraindication. If K2 supplementation is clinically indicated (e.g., osteoporosis) in a warfarin patient, coordinate closely: the warfarin dose may need upward titration, and consistency in K2 dose is essential. - **Known hypersensitivity to K2 or carrier oils (soybean, peanut, etc.) in the specific product.** Rare but possible; switch product or form. **Relative contraindications / caution:** - **Active thromboembolic disease or recent PE/DVT:** K2 does not directly cause thrombosis in non-anticoagulated individuals, but in patients with active clotting issues or on vitamin K antagonist therapy, any change in K intake warrants close clinical attention. - **Mechanical heart valves on warfarin:** particularly sensitive to INR destabilization; K2 changes require anticoagulation clinic coordination. - **Severe fat malabsorption (bile duct obstruction, severe pancreatic insufficiency, extensive small bowel resection):** K2 absorption may be substantially reduced. Consider parenteral vitamin K under clinician supervision if deficiency-related symptoms develop. - **Advanced liver disease (cirrhosis Child-Pugh B or C):** hepatocellular synthesis of VKDPs is impaired and parenteral vitamin K may be needed. Discuss with hepatologist before adding K2 supplements. - **Known glucose-6-phosphate dehydrogenase (G6PD) deficiency:** high-dose water-soluble vitamin K analogs (K3/menadione, no longer used in human medicine) caused hemolysis in G6PD deficiency; natural K1 and K2 at nutritional/supplemental doses are safe. Menadione should not be used; K2 (MK-7, MK-4) is appropriate. **Drug interactions warranting awareness:** - **Warfarin, acenocoumarol, phenprocoumon:** see above. Critical. - **DOACs (apixaban, rivaroxaban, edoxaban, dabigatran):** no interaction; K2 is safe. - **Aspirin, clopidogrel, other antiplatelets:** no interaction; K2 is safe. - **Heparin, LMWH, fondaparinux:** no K interaction; safe. - **Bile acid sequestrants (cholestyramine, colestipol, colesevelam):** reduce fat-soluble vitamin absorption; separate K2 by ≥2 hours. - **Orlistat:** reduces fat absorption; take K2 at different time. - **Mineral oil (chronic use):** reduces fat-soluble vitamin absorption; avoid or separate. - **Broad-spectrum antibiotics (especially long courses):** may reduce gut flora vitamin K2 production; clinically minor since supplements and diet contribute most K2 intake. - **Phenytoin and other enzyme-inducing anticonvulsants:** can increase vitamin K metabolism; may affect dose requirements in patients with specific clinical indications. - **Long-term high-dose vitamin A (retinol >10,000 IU chronically):** theoretical antagonism with K2 at transcriptional level; avoid unnecessary high-dose retinol. **Populations requiring clinician input before initiation:** - Patients on any vitamin K antagonist (most important) - Patients with active thromboembolism - Patients with mechanical heart valves - Patients with advanced liver disease - Patients with severe chronic kidney disease on hemodialysis (K2 may be beneficial but should be coordinated) - Children (pediatric dosing is age-based; routine supplementation is not typically indicated beyond infancy) - Pregnant women (K2 appears safe at typical supplemental doses but routine high-dose supplementation is not established; standard prenatal vitamins contain adequate K1) **Neonatal considerations:** - All newborns in most countries should receive the standard IM vitamin K1 injection (1 mg phylloquinone) within hours of birth to prevent vitamin K deficiency bleeding of the newborn (VKDB), a potentially fatal condition. This is one of the best-validated public health interventions in newborn medicine with overwhelming evidence and decades of safety experience. - Declining the injection based on misinformation substantially increases VKDB risk, including late-onset VKDB which can present with intracranial hemorrhage. - Oral regimens are alternatives in some jurisdictions but provide less reliable protection than the IM injection. - K2 supplementation does not replace the standard neonatal K1 injection. **Overdose and emergency:** - Adult overdose of K2 at typical supplement doses is not known to produce clinical toxicity. - Accidental ingestion of large quantities (multiple bottles) has not been reported to produce toxicity syndromes in case reports. - In a warfarin patient with accidental K ingestion (e.g., large dose of K1 or K2), the immediate concern is INR reversal and thrombosis risk; management is with additional warfarin dose over subsequent days and close INR monitoring. - Management of any concerning ingestion: call poison control (1-800-222-1222 in US). **Allergies and sensitivities:** - Rare sensitivity to K2 itself - More common: reaction to capsule excipients (soybean oil, MCT, gelatin, titanium dioxide). Switching to a different formulation usually resolves. - Patients with soy allergy: verify K2 source is not soy-derived; most MK-7 is fermented from soy (natto), though purification removes most soy protein. Alternative sources exist (Bacillus subtilis fermentation without soy substrate); check product specification. **Pediatric specific:** - Oral pediatric supplementation is not routinely indicated beyond the neonatal period. - Children with cystic fibrosis, cholestatic liver disease, inflammatory bowel disease, or other malabsorption syndromes may require vitamin K supplementation—management should be by pediatric specialist. **Pre-operative considerations:** - Routine oral K2 at 100-200 mcg does not affect surgical bleeding in non-anticoagulated patients. - Patients on warfarin undergoing surgery typically have warfarin held or bridged; any K2 intake should be disclosed to the surgical team but typically does not require special management at nutritional doses. - Pharmacologic doses of K1 or K2 given pre-operatively may be used specifically to reverse warfarin—this is a medical management decision, not a patient-initiated one. In practical terms, for the non-anticoagulated adult, K2 is among the safest vitamins to supplement, with an excellent safety margin and no toxicity syndrome at any tested dose. The anticoagulation issue is the single dominant clinical concern and deserves careful attention when relevant.
Additional Notes
Forms and dose equivalence:
MK-7 (menaquinone-7): The long-chain menaquinone of primary interest for adult supplementation. Plasma half-life ~72 hours. Typical supplementation doses:
- Nutritional maintenance: 45-100 mcg/day
- General optimization: 100-200 mcg/day (most common)
- Therapeutic target (Knapen bone trial): 180 mcg/day
- Higher-dose investigational: 360-720 mcg/day
MK-4 (menaquinone-4, menatetrenone): Short-chain menaquinone with short plasma half-life (~1-3 hours) requiring pharmacologic dosing for sustained effect. Typical supplementation doses:
- Low-dose supplemental: 1-5 mg/day (some evidence of activity; generally considered insufficient to match MK-7's daily effect)
- Osteoporosis therapeutic (Japan): 15 mg TID = 45 mg/day (Glakay dose)
- Split dosing is important for MK-4: 3-times-daily dosing substantially outperforms single daily dose due to short half-life
MK-9 (menaquinone-9): Less commonly available as supplement; found in hard cheeses and some fermented dairy. Activity profile intermediate between MK-4 and MK-7. Rarely targeted specifically in supplementation.
Vitamin K1 (phylloquinone): Leafy-green source; supports coagulation preferentially but limited extrahepatic reach. Dose 90-120 mcg/day is the U.S. adequate intake. Supplementation is less common given abundant dietary K1 in reasonable diets.
MCT-based or fat-carrier formulations: Many MK-7 products use medium-chain triglycerides or soybean oil as carriers to aid fat-soluble absorption. Take with a fat-containing meal for best absorption whether or not the product includes oil.
Timing considerations:
- With a fat-containing meal: best absorption. Breakfast with eggs/butter/avocado or lunch/dinner with healthy fat is ideal. Empty-stomach absorption is reduced.
- Once daily for MK-7: sufficient given 72-hour half-life.
- Multiple times daily for MK-4: 2-3x daily due to short half-life if aiming for sustained activity.
- Alongside vitamin D: convenient to dose D3 and K2 together given both are fat-soluble; no biochemical requirement for same-time dosing but practical.
Time to biological effect:
- Osteocalcin carboxylation (ucOC normalization): 2-4 weeks at 180 mcg MK-7
- MGP carboxylation (dp-ucMGP reduction): 4-8 weeks at 180 mcg MK-7
- Bone mineral density changes (DEXA): 1-3 years
- Arterial stiffness markers (pulse wave velocity): 1-3 years
- No acute or subjective effect expected—K2 is a slow-burn foundational intervention
Dose adjustment guidance:
- If no subjective effect: this is expected. K2 does not produce acute subjective benefit; outcomes are slow-motion and measured via biomarkers or long-term clinical endpoints.
- If on warfarin: do NOT adjust without anticoagulation clinic coordination.
- If new bruising or bleeding in non-anticoagulated individual: unlikely to be K2 related; pursue standard workup (CBC, coagulation panel, platelet studies).
Cycling: Not required. K2 is intended for indefinite daily use.
Measurement:
- PT/INR: insensitive to peripheral K status; mainly reflects hepatic coagulation factor adequacy. Normal PT/INR does not rule out extrahepatic K deficiency.
- Undercarboxylated osteocalcin (ucOC): sensitive to bone K status. Often reported as ucOC/total OC ratio. Available at specialty labs.
- Dephospho-uncarboxylated MGP (dp-ucMGP): sensitive to vascular K status. Elevated levels associated with cardiovascular events. Available at specialty labs; most widely measured K biomarker in research.
- Plasma K1 and MK concentrations: reflect recent intake; limited for long-term status assessment.
Most users do not require baseline testing; prior probability of subclinical K2 inadequacy is high in Western populations, and supplementation at 100-200 mcg MK-7 daily is low-risk and low-cost. Testing is informative if pursuing targeted clinical goals (osteoporosis, CKD, vascular calcification).
Typical product landscape:
- Standalone MK-7: 100-200 mcg per capsule; look for MenaQ7 branded ingredient (has most clinical trial support) or quality generic
- D3 + K2 combinations: very common; verify both elemental doses on the Supplement Facts panel
- MK-7 + MK-4 combinations: available; marginal benefit over MK-7 alone
- Pharmaceutical MK-4 (Japan): Glakay brand, 15 mg capsules; available as import for Western users
- Cost range: $8-25 per month for MK-7 100-200 mcg daily; $80-150+/month for pharmaceutical MK-4 45 mg regimens
Quality considerations:
- MenaQ7 (Norwegian manufacturer NattoPharma/Kappa Bioscience) is the trademark-holder for the MK-7 used in most clinical trials and has the strongest quality-control and evidence chain
- All-trans vs cis MK-7: the all-trans isomer is the biologically active form; high-quality products specify ≥99% all-trans. Some cheap generic MK-7 contains lower all-trans percentage with reduced activity.
- Third-party testing: USP, NSF, ConsumerLab verification is preferred when available
In summary, for most adults the simplest and most evidence-based K2 regimen is MK-7 100-200 mcg daily with a fat-containing meal, alongside D3 and other foundational supplements.
Frequently Asked Questions
What is the recommended Vitamin K2 dosage?
Dosage for Vitamin K2 varies by protocol. Consult a qualified healthcare provider.
How often should I take Vitamin K2?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Vitamin K2 need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Vitamin K2 side effects?
Vitamin K2 has an exceptionally favorable safety profile in non-warfarin patients at all currently studied doses. No clinical toxicity syndrome has been identified for K2 in the dose ranges used in clinical trials or typical supplementation, and no tolerable upper limit has been established by the Institute of Medicine or European Food Safety Authority. This contrasts with fat-soluble vitamins A, D, and E, each of which has well-characterized toxicity at pharmacologic doses. The biological reason for K2's wide safety margin is that its sole biochemical role—activation of GGCX for VKDP carboxylation—is self-limited once all target substrate is carboxylated; excess K does not drive additional downstream effects. Endogenous regulation via the vitamin K cycle (VKOR) recycles vitamin K continuously, minimizing net demand even at high intakes. **Reported adverse effects at supplement doses (100-200 mcg MK-7 or 15-45 mg MK-4):** - Rare gastrointestinal upset, mild nausea - Very rare allergic reaction (to capsule excipients more than to K2 itself) - No hepatic toxicity - No renal toxicity - No effect on platelet function or bleeding time in non-warfarin individuals - No interference with coagulation in patients not on vitamin K antagonists **Critical interaction: vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon).** This is the single most important safety consideration for vitamin K2. Warfarin works by depleting reduced vitamin K through VKOR inhibition, preventing coagulation factor carboxylation. Supplemental vitamin K (any form) directly opposes warfarin's effect and can lower INR, risking thrombotic events. The magnitude of interaction depends on dose: - **Acute high-dose vitamin K** (e.g., 5-10 mg given to reverse warfarin in over-anticoagulation): rapidly lowers INR within hours to days - **Chronic low-dose K2 supplementation (100-200 mcg MK-7)**: can modestly lower INR and destabilize warfarin control, though the effect is smaller than with equivalent dietary K1 variability - **Chronic moderate-dose K2 (MK-4 15-45 mg)**: can meaningfully lower INR and requires warfarin dose adjustment The practical guidance is that warfarin patients should NOT start K2 supplementation without coordination with their anticoagulation clinic. If K2 supplementation is indicated (e.g., for osteoporosis), the warfarin dose can be titrated upward to maintain INR, but the key is consistency—avoid starting, stopping, or changing K2 dose without monitoring. Direct oral anticoagulants (DOACs: apixaban, rivaroxaban, edoxaban, dabigatran) do not involve vitamin K, so K2 supplementation is safe with these medications without dose adjustment. **Natto allergy (rare):** Natto is a rich MK-7 source but contains other compounds (including nattokinase, spore-forming bacteria residuals) that can trigger allergic reactions in sensitized individuals. Supplement-form MK-7 is typically produced via Bacillus subtilis natto fermentation but is purified; true allergy to MK-7 is rare. **Population-specific safety considerations:** *Pregnancy and lactation:* Vitamin K is safe in pregnancy within physiological ranges; deficiency produces neonatal hemorrhagic disease (classical indication for routine neonatal vitamin K injection). Supplemental K2 in pregnancy has not been extensively studied but is not known to be harmful at typical doses. The U.S. recommends 90 mcg/day total vitamin K for pregnant and lactating women. *Neonates:* All newborns in most countries receive a single IM injection of phylloquinone 1 mg at birth to prevent vitamin K deficiency bleeding of the newborn. Oral regimens are alternatives in some jurisdictions but provide less reliable protection. Parents who decline the injection based on misinformation substantially increase risk of serious or fatal hemorrhage; this is a well-validated intervention with overwhelming evidence. *Infants and young children:* Pediatric supplementation doses track age-based adequate intake (AI: 2 mcg/day for 0-6 months, scaling up). K2 is not typically supplemented in healthy children beyond infancy. *Elderly:* No specific concerns; K2 supplementation is generally beneficial in this population given higher rates of subclinical deficiency and osteoporosis risk. *Patients with malabsorption (Crohn's, celiac, short bowel syndrome, biliary obstruction):* At risk for fat-soluble vitamin deficiency; K2 supplementation often indicated but absorption may be impaired. Higher doses may be needed. Consider monitoring (PT/INR for gross deficiency; ucOC or dp-ucMGP for subclinical deficiency where testing is available). *Patients with chronic kidney disease:* CKD patients (especially dialysis patients) show accelerated vascular calcification and higher rates of vitamin K functional deficiency (elevated dp-ucMGP). K2 supplementation is under active research in this population; small trials suggest MK-7 improves MGP carboxylation, though hard outcome data are pending. CKD patients on warfarin are at particular risk of calciphylaxis, making the vitamin K antagonist choice increasingly questioned. *Patients with liver disease:* K2 absorption requires bile; cholestatic liver disease impairs uptake. Hepatocellular synthesis of VKDPs (including coagulation factors) depends on hepatocyte function. Patients with advanced liver disease may require parenteral K supplementation under clinician guidance. **Interactions with other medications:** - **Statins:** No clinically significant interaction. Some theoretical concern that statins reduce endogenous MK-4 synthesis via mevalonate pathway inhibition, but direct evidence is limited. - **Bile acid sequestrants (cholestyramine, colestipol):** Can reduce fat-soluble vitamin absorption; separate by several hours. - **Orlistat:** Reduces fat absorption; can reduce fat-soluble vitamin uptake. Take K2 at different time from orlistat. - **Broad-spectrum antibiotics, especially long courses:** May reduce gut bacterial K2 production, though the clinical significance for supplementation is minor (diet and supplements contribute more than gut synthesis to total vitamin K). - **DOACs (apixaban, rivaroxaban, etc.):** No interaction. Safe to supplement K2. **Overdose:** No clinically significant overdose syndrome has been reported for K2 in adults. Accidental ingestion of large quantities (e.g., full bottles of supplement) has not produced toxicity syndromes in case reports. Management is supportive. In summary, vitamin K2 is among the safest vitamins to supplement, with the singular important exception of its interaction with vitamin K antagonist anticoagulants. Warfarin patients should coordinate closely with their anticoagulation clinic; DOAC patients and non-anticoagulated individuals can supplement without meaningful safety concern.
Where can I buy Vitamin K2?
Visit our vendor directory to find trusted sources for Vitamin K2.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
